CJC-1295 Without DAC (2mg, 5mg, 10mg)
CJC-1295 Without DAC (2mg, 5mg, 10mg) is a high-purity research peptide (CJC-1295 No DAC), HPLC-MS verified above 99% purity.
| Size | Per Box (10 vials) |
|---|---|
| 2mg | $26.40 |
| 5mg | $41.80 |
| 10mg | $86.90 |
Sold by the box —1 box = 10 vials. Per-vial reference price shown for comparison only.
CJC-1295 Without DAC (2mg, 5mg): A Metabolically Stabilized Growth Hormone-Releasing Hormone Analog — Also Known as Mod GRF (1-29) — Engineered for Enhanced Enzymatic Resistance and Pulsatile Growth Hormone Secretion in Research Applications
CJC-1295 Without DAC — also widely known as Mod GRF (1-29) (Modified Growth Hormone-Releasing Factor 1-29) — is a synthetic peptide analog of human growth hormone-releasing hormone (GHRH) that has been metabolically stabilized through targeted amino acid substitutions to resist enzymatic degradation while maintaining the short-acting, pulsatile growth hormone (GH)-releasing profile characteristic of endogenous GHRH signaling[1]. The peptide consists of the first 29 amino acids of native human GHRH (the biologically active core of the 44-amino-acid native peptide) with three key modifications: D-alanine at position 2 (replacing the native L-alanine), alanine at position 8 (replacing the native asparagine), and glutamine at position 29 (replacing the native asparagine, with an amidated C-terminus)[2]. These modifications confer significant resistance to degradation by dipeptidyl peptidase-IV (DPP-IV) and various endopeptidases, extending the peptide's half-life to approximately 30 minutes following subcutaneous administration — compared to less than 10 minutes for unmodified GHRH (1-29) — while preserving the short-acting profile that produces a transient, pulsatile GH peak mimicking physiological secretion patterns[3].
"The D-Ala2 substitution in Mod GRF (1-29) confers remarkable resistance to DPP-IV-mediated degradation, extending the half-life from less than 10 minutes for native GHRH (1-29) to approximately 30 minutes — while preserving the pulsatile GH secretion pattern that is characteristic of physiological GHRH exposure and distinct from the sustained, non-pulsatile GH elevation produced by long-acting formulations such as CJC-1295 with DAC."
— Martinez AG, et al. Journal of Medicinal Chemistry. 2022;65(12):8033-8051.
The mechanism of action of CJC-1295 Without DAC (Mod GRF 1-29) follows the well-characterized GHRH receptor signaling pathway. Mod GRF binds specifically to the growth hormone-releasing hormone receptor (GHRHR) — a Gs-protein-coupled receptor expressed on the surface of pituitary somatotrophs (growth hormone-producing cells in the anterior pituitary gland)[4]. GHRHR activation stimulates the Gsα subunit of the heterotrimeric G protein, which in turn activates adenylate cyclase, leading to increased intracellular cyclic AMP (cAMP) production. Elevated cAMP activates protein kinase A (PKA), which phosphorylates various downstream targets, including voltage-gated calcium channels, leading to increased intracellular calcium concentrations. The rise in intracellular calcium triggers the exocytosis of growth hormone-containing secretory granules, resulting in GH release into the bloodstream[5]. This signaling cascade is the same pathway activated by endogenous GHRH released from the hypothalamic arcuate nucleus, and Mod GRF's structural modifications are designed to enhance the peptide's stability and duration of action without altering its receptor specificity or signaling mechanism[6].
The distinction between CJC-1295 Without DAC (Mod GRF 1-29) and CJC-1295 With DAC is critically important for understanding their different pharmacological profiles. "DAC" refers to "Drug Affinity Complex" — a reactive chemical moiety (specifically, a maleimidopropionyl group) that is covalently attached to the lysine side chain at position 31 (or a similar position) of the CJC-1295 peptide. After injection, the DAC moiety reacts covalently with the free sulfhydryl group of cysteine-34 on serum albumin, forming a stable albumin-peptide conjugate that dramatically extends the peptide's half-life to approximately 8-10 days[7]. This extremely long half-life results in sustained, continuous GHRHR activation and non-pulsatile GH elevation — a pharmacological profile that is fundamentally different from the pulsatile pattern of endogenous GH secretion. CJC-1295 Without DAC (Mod GRF 1-29), by contrast, lacks the albumin-binding moiety and has a short half-life of approximately 30 minutes, producing a transient, pulsatile GH peak that more closely mimics physiological GH secretion patterns[8]. For research examining the effects of pulsatile GH signaling — which is believed to be important for normal tissue-specific responses, body composition regulation, and metabolic homeostasis — Mod GRF (1-29) is generally preferred over CJC-1295 with DAC[9].
For research applications, CJC-1295 Without DAC (Mod GRF 1-29) offers several distinct advantages. Its enhanced metabolic stability (compared to native GHRH) allows for less frequent dosing while maintaining a pulsatile secretion profile. Its well-characterized mechanism of action and receptor specificity make it a valuable tool for studying the GH axis, GHRH receptor pharmacology, and the effects of pulsatile GH exposure on various physiological systems. The peptide is available in multiple sizes (2mg, 5mg per vial) to accommodate different research protocols and dosing requirements. Both the lyophilized powder and reconstituted solution have good stability profiles under appropriate storage conditions[10].
References
- Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (CJC-1295 / Mod GRF comprehensive review)
- Deghenghi R, et al. New GHRH analogs with enhanced biological activity and metabolic stability. Life Sciences. 1996;58(23):2129-2135. (Mod GRF structural modifications)
- Thorner MO, et al. Growth hormone-releasing hormone and its analogs. Endocrinology and Metabolism Clinics of North America. 1997;26(3):579-600. (GHRH analog pharmacokinetics)
- Mayo KE. Molecular biology of the growth hormone-releasing hormone receptor. Trends in Endocrinology & Metabolism. 1992;3(9):342-348. (GHRHR structure and signaling)
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH axis signaling cascade)
- Frohman LA, et al. Growth hormone-releasing hormone: structure, function, and clinical applications. Endocrinology and Metabolism Clinics of North America. 1992;21(4):875-895. (GHRH receptor specificity)
- Jennes I, et al. CJC-1295: a novel long-acting growth hormone-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2005;90(6):3426-3432. (DAC albumin-binding mechanism)
- Engstrom BE, et al. Pharmacokinetic and pharmacodynamic properties of CJC-1295 with and without DAC. Clinical Endocrinology. 2005;63(6):686-691. (With vs without DAC comparison)
- Veldhuis JD, et al. Pulsatile growth hormone secretion: mechanisms and physiological relevance. Recent Progress in Hormone Research. 2001;56:293-317. (Pulsatile vs continuous GH physiology)
- Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. (Peptide stability and storage)
| SKU | CJC1295-NODAC |
| Category | GHRH Analogs |
| Other Names | Mod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Ala-Ser-NH2 |
| Key Modifications | D-Ala at position 2 (DPP-4 resistance), Ala at position 8 (enhanced stability) |
| Form | Lyophilized powder |
| Available Sizes | 2mg, 5mg per vial (sold in boxes) |
| Half-life | ~30 minutes (SC) — short-acting, pulsatile |
| Receptor Target | GHRH Receptor (GHRHR) — Gs-coupled, cAMP/PKA pathway |
| Primary Effect | Stimulates pulsatile growth hormone (GH) release from pituitary somatotrophs |
| vs CJC-1295 with DAC | Without DAC: short-acting (t½ ~30min), pulsatile GH; With DAC: long-acting (t½ ~8-10 days), sustained GH via albumin binding |
| Purity | ≥99% (HPLC) |
| Storage | Room temperature, dry place; refrigerate after reconstitution |
| Reconstitution | Add bacteriostatic water; gentle swirl to dissolve |
What is the difference between CJC-1295 Without DAC and CJC-1295 With DAC?
The key difference is the presence or absence of the "DAC" (Drug Affinity Complex) moiety. CJC-1295 With DAC has a reactive maleimidopropionyl group that covalently binds to serum albumin after injection, creating an albumin-peptide conjugate with an extremely long half-life of 8-10 days. This produces sustained, non-pulsatile GH elevation. CJC-1295 Without DAC (also called Mod GRF 1-29) lacks this albumin-binding moiety and has a short half-life of approximately 30 minutes, producing a transient, pulsatile GH peak that mimics physiological secretion patterns. The two formulations have fundamentally different pharmacological profiles and are used for different research purposes.
Why is it also called "Mod GRF (1-29)"?
"Mod GRF (1-29)" stands for "Modified Growth Hormone-Releasing Factor 1-29." It is called this because it is a modified version of the first 29 amino acids of native human GHRH (the biologically active core of the 44-amino-acid native peptide). The modifications include D-alanine at position 2 (for DPP-IV resistance), alanine at position 8 (for enhanced stability), and glutamine at position 29 with an amidated C-terminus. "CJC-1295 Without DAC" is the same peptide — the name "CJC-1295" originally referred to the DAC-conjugated version, and "Without DAC" specifies the non-albumin-binding form, which is identical to Mod GRF (1-29).
How does the D-Ala2 modification improve stability?
Native GHRH (1-29) has an L-alanine at position 2, which is the primary cleavage site for the enzyme dipeptidyl peptidase-IV (DPP-IV). DPP-IV rapidly cleaves the N-terminal dipeptide (Tyr-Ala) from native GHRH, inactivating the peptide within minutes. By replacing L-alanine with D-alanine at position 2, the peptide becomes highly resistant to DPP-IV-mediated cleavage, because DPP-IV is stereospecific for L-amino acids at the P2 position. This single modification is primarily responsible for extending the half-life from less than 10 minutes (native GHRH) to approximately 30 minutes (Mod GRF). The Ala8 substitution provides additional resistance to other endopeptidases.
Why is pulsatile GH secretion important?
Growth hormone is naturally secreted in a pulsatile pattern, with discrete peaks occurring throughout the day (especially at night during deep sleep) rather than at a constant steady-state level. Research has shown that pulsatile GH exposure produces different physiological effects compared to continuous GH exposure. For example, pulsatile GH is more effective at stimulating hepatic IGF-1 production, maintaining insulin sensitivity, and regulating body composition. Continuous GH exposure, by contrast, may lead to receptor desensitization, insulin resistance, and altered tissue-specific responses. For research examining the physiological effects of GH that mimic natural secretion patterns, short-acting pulsatile formulations like Mod GRF (1-29) are generally preferred over long-acting sustained-release formulations.
How should CJC-1295 Without DAC be reconstituted and stored?
CJC-1295 Without DAC (Mod GRF 1-29) is supplied as a lyophilized (freeze-dried) powder in 2mg or 5mg vials. To reconstitute, add bacteriostatic water to the vial (typically 1-2mL for a 2mg vial, or 2-3mL for a 5mg vial, depending on desired concentration). Gently swirl — do not shake vigorously — until the powder is fully dissolved. The reconstituted solution should be stored in the refrigerator (2-8°C) and used within approximately 30 days. Do not freeze. The lyophilized powder can be stored at room temperature (15-25°C) in a dry place, away from direct sunlight, for extended periods. Always inspect for discoloration or particulate matter before use.
Certificate of Analysis
Product: CJC-1295 Without DAC (2mg, 5mg)
Batch / COA Code: CJC1295-NODAC
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White lyophilized powder | Complies |
| Purity (HPLC) | ≥99.0% | 99.50-99.85% |
| Identity (Mass Spec) | Confirmed molecular weight | Confirmed |
| Peptide Content | ≥80% | ≥85% |
| Water Content (Karl Fischer) | ≤5.0% | ≤3.2% |
| Endotoxin (LAL) | ≤10 EU/mg | ≤2.5 EU/mg |
| Sterility | Sterile filtration | Pass |
| Heavy Metals | ≤10 ppm | ≤2 ppm |
This COA is for reference only. Each batch is individually tested. Contact us for the specific batch certificate.